Ly333531

All phytochemicals (baicalein, Cat# 465119 (>98%); flavone, Cat# F2003 (>99%); genistein, Cat# G6776 (~98%); α-naphthoflavone, Cat# N5757 (>98%); luteolin, Cat# L9283 (>98%); naringenin, Cat# N5893 (>95%); quercetin, Cat# Q0125 (>98%); resveratrol, Cat# R5010 (>99%); chrysin, Cat# C80105 (>97%); hesperetin, Cat# W431300 (>95%); and isoliquiritigenin, Cat# I3766 (>98%)) were obtained from Sigma Chemical (St Louis, MO, USA). The impurities of the phytochemicals could be a confounding factor. Kinase inhibitors, including SB203580 (Cat# 559389, Merck), H-89 (Cat# 371963, Merck), Compound C (Cat# 171260, Merck), Bisindolylmaleimide I (Cat# 203290, Merck), pAKT inhibitor (Cat# 124011, Merck) and U0126 (Cat# 662005, Merck), were purchased from Calbiochem (San Diego, CA, USA). LY333531 (Cat# sc-364215) and HBDDE (Cat# sc-202174) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). SP600125 (Cat# S5567) and all other chemicals, if not stated, were acquired from Sigma Chemicals (St Louis, MO, USA).

BIMs I-XI and the PKC inhibitor LY 333531 (also known as ruboxistaurin), that contains a BIM core, were provided by Santa Cruz Biotechnology (Dallas, Texas) and Sigma-Aldrich (Saint-Quentin Fallavier, France). The chemical structures of these BIMs are shown in Fig 1. Verapamil, cyclosporin A, Gö 6983, amitriptyline, U0126, wortmannin, KN62, staurosporine, chelerythrine, tetra-ethylammonium (TEA), 4',6-diamidino-2-phenylindole (DAPI) and phorbol-12-myristate-13-acetate (PMA) were purchased by Sigma-Aldrich (Saint-Quentin Fallavier, France). [1-¹⁴C]-TEA (sp. act. 2.4 mCi/mmol) and [³H(G)] taurocholic acid (sp. act. 1.19 Ci/mmol) were from Perkin-Elmer (Boston, MA). All other chemicals were commercial products of the highest purity available.